Cargando…

Population Pharmacokinetic Model and Meta-analysis of Outcomes of Amphotericin B Deoxycholate Use in Adults with Cryptococcal Meningitis

There is a limited understanding of the population pharmacokinetics (PK) and pharmacodynamics (PD) of amphotericin B deoxycholate (DAmB) for cryptococcal meningitis. A PK study was conducted in n = 42 patients receiving DAmB (1 mg/kg of body weight every 24 h [q24h]). A 2-compartment PK model was de...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stott, Katharine E., Beardsley, Justin, Whalley, Sarah, Kibengo, Freddie Mukasa, Mai, Nguyen Thi Hoang, Kolamunnage-Dona, Ruwanthi, Hope, William, Day, Jeremy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2018
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6021666/ https://www.ncbi.nlm.nih.gov/pubmed/29735567 http://dx.doi.org/10.1128/AAC.02526-17

Ejemplares similares

Population Pharmacokinetics and Cerebrospinal Fluid Penetration of Fluconazole in Adults with Cryptococcal Meningitis
por: Stott, Katharine E., et al.
Publicado: (2018)

Population Pharmacodynamics of Amphotericin B Deoxycholate for Disseminated Infection Caused by Talaromyces marneffei
por: Le, Thuy, et al.
Publicado: (2019)

Toxicity of Amphotericin B Deoxycholate-Based Induction Therapy in Patients with HIV-Associated Cryptococcal Meningitis
por: Bicanic, Tihana, et al.
Publicado: (2015)

A randomized open label trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis.
por: Ngan, Nguyen Thi Thuy, et al.
Publicado: (2019)

An open label randomized controlled trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis
por: Ngan, Nguyen Thi Thuy, et al.
Publicado: (2021)

Experimental Models of Short Courses of Liposomal Amphotericin B for Induction Therapy for Cryptococcal Meningitis
por: Lestner, Jodi, et al.
Publicado: (2017)

Quality of life and associated factors among HIV positive patients after completion of treatment for Cryptococcal meningitis
por: Kitonsa, Jonathan, et al.
Publicado: (2021)

Prevalence and Hospital Management of Amphotericin B Deoxycholate-Related Toxicities during Treatment of HIV-Associated Cryptococcal Meningitis in South Africa
por: Meiring, Susan, et al.
Publicado: (2016)

Population pharmacokinetics of liposomal amphotericin B in adults with HIV-associated cryptococcal meningoencephalitis
por: Stott, Katharine E, et al.
Publicado: (2022)

1331. High direct costs caused by Cryptococcal meningitis treated with Amphotericin B deoxycholate in a public hospital in Lima, Peru. 2021-2022
por: Vilcarromero, Stalin, et al.
Publicado: (2023)

Efficacy of an Abbreviated Induction Regimen of Amphotericin B Deoxycholate for Cryptococcal Meningoencephalitis: 3 Days of Therapy Is Equivalent to 14 Days
por: Livermore, Joanne, et al.
Publicado: (2014)

Do Intracerebral Cytokine Responses Explain the Harmful Effects of Dexamethasone in Human Immunodeficiency Virus–associated Cryptococcal Meningitis?
por: Beardsley, Justin, et al.
Publicado: (2019)

Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis
por: Jarvis, Joseph N, et al.
Publicado: (2022)

Determinants of two-year mortality among HIV positive patients with Cryptococcal meningitis initiating standard antifungal treatment with or without adjunctive dexamethasone in Uganda
por: Kitonsa, Jonathan, et al.
Publicado: (2020)

Comparison of amphotericin B deoxycholate in combination with either flucytosine or fluconazole, and voriconazole plus flucytosine for the treatment of HIV-associated cryptococcal meningitis: a prospective multicenter study in China
por: Zhao, Ting, et al.
Publicado: (2022)

Paradoxical respiratory failure due to cryptococcal pneumonia after amphotericin B treatment for HIV-associated cryptococcal meningitis
por: Scriven, James E., et al.
Publicado: (2018)

Efficacy of intravenous amphotericin B-polybutylcyanoacrylate nanoparticles against cryptococcal meningitis in mice
por: Xu, Nan, et al.
Publicado: (2011)

A Novel Cryptococcal Meningitis Therapy: The Combination of Amphotericin B and Posaconazole Promotes the Distribution of Amphotericin B in the Brain Tissue
por: Yang, Ming, et al.
Publicado: (2020)

Acute hepatic injury with amphotericin B deoxycholate in an immunocompetent patient
por: Wagner, Jamie L., et al.
Publicado: (2016)

Effect of deoxycholate, amphotericin B and fongizone on transmissible gastroenteritis coronavirus
por: Nguyen, T.D., et al.
Publicado: (1987)

Case report: Reversible encephalopathy associated with liposomal amphotericin B in a patient with cryptococcal meningitis
por: Luo, Si, et al.
Publicado: (2022)

869. Oral Encochleated Amphotericin B for Cryptococcal Meningitis: a Phase II Randomized Trial
por: Atukunda, Mucunguzi, et al.
Publicado: (2022)

In vitro activities of amphotericin B deoxycholate and liposomal amphotericin B against 604 clinical yeast isolates
por: Montagna, Maria Teresa, et al.
Publicado: (2014)

Factors affecting mortality among HIV positive patients two years after completing recommended therapy for Cryptococcal meningitis in Uganda
por: Kitonsa, Jonathan, et al.
Publicado: (2019)

A Phase 3 Study of Micafungin Versus Amphotericin B Deoxycholate in Infants With Invasive Candidiasis
por: Benjamin, Daniel K., et al.
Publicado: (2018)

Amphotericin B lipid complex: treatment of invasive fungal infections in patients refractory to or intolerant of amphotericin B deoxycholate
por: Chandrasekar, PH
Publicado: (2008)

Cerebrospinal Fluid Culture Positivity and Clinical Outcomes After Amphotericin-Based Induction Therapy for Cryptococcal Meningitis
por: Rolfes, Melissa A., et al.
Publicado: (2015)

Continuous versus Conventional Infusion of Amphotericin B Deoxycholate: A Meta-Analysis
por: Falagas, Matthew E., et al.
Publicado: (2013)

Successful Treatment of Protothecal Tenosynovitis in an Immunocompetent Patient using Amphotericin B Deoxycholate
por: Kim, Ji-Eun, et al.
Publicado: (2017)

Cyanotic Raynaud's phenomenon induced by amphotericin B deoxycholate: A case report
por: Hatem, Nayla A., et al.
Publicado: (2023)

Short-Course Induction Treatment with Intrathecal Amphotericin B Lipid Emulsion for HIV Infected Patients with Cryptococcal Meningitis
por: Alvarez-Uria, Gerardo, et al.
Publicado: (2015)

Liposomal and Deoxycholate Amphotericin B Formulations: Effectiveness against Biofilm Infections of Candida spp.
por: Rodrigues, Célia F., et al.
Publicado: (2017)

Amphotericin B deoxycholate for relapse visceral leishmaniasis in Bangladesh: a cross-sectional study
por: Hasnain, Md Golam, et al.
Publicado: (2018)

Standardized Electrolyte Supplementation and Fluid Management Improves Survival During Amphotericin Therapy for Cryptococcal Meningitis in Resource-Limited Settings
por: Bahr, Nathan C., et al.
Publicado: (2014)

Evaluating statistical characteristics of biomarker-guided trial designs
por: Antoniou, Miranta, et al.
Publicado: (2015)

Sample size formula for joint modelling of longitudinal and time-to-event data in clinical trials
por: Powney, Matthew, et al.
Publicado: (2013)

Adjusting for informative missing outcome data in clinical trials with longitudinal study designs
por: Kolamunnage-Dona, Ruwanthi, et al.
Publicado: (2013)

Population Pharmacokinetics of Praziquantel in Pregnant and Lactating Filipino Women Infected with Schistosoma japonicum
por: Bustinduy, Amaya L., et al.
Publicado: (2020)

Treatment of Cryptococcal Meningitis: How Have We Got Here and Where are We Going?
por: Ngan, Nguyen Thi Thuy, et al.
Publicado: (2022)

Cryptococcal meningitis: A neglected NTD?
por: Molloy, Síle F., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_m5j28r3u09i6uv3qjsba2ti106